Great Neck, NYNCT07103746Now EnrollingIRB Ready

Necrotizing Myopathy Clinical Trial in Great Neck, NY

Access cutting-edge necrotizing myopathy treatment through this phase 2 clinical trial at a research site in Great Neck. Study-provided care at no cost to qualified participants.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)

Quick Self-Assessment

See if you qualify for this Great Neck location

Preparing your pre-screening questions…

Expert Care in Great Neck

Access necrotizing myopathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related necrotizing myopathy treatment provided free

Apply for This Great Neck Location

Check if you qualify for this necrotizing myopathy clinical trial in Great Neck, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Great Neck

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Great Neck site if eligible
  4. 4Begin participation

About This Necrotizing Myopathy Study in Great Neck

This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy. The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks compared to placebo in treating early, active autoantibody positive immune-mediated necrotizing myopathy using the validated 2016 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Myositis Resp

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Who Can Participate

Inclusion Criteria

Participant must be able to understand and provide informed consent.
Age 18 years or older at disease onset.
Definite or probable IIM per the 2017 EULAR/ACR classification criteria.
Diagnosis of IMNM, meeting the 2016 ENMC classification criteria and having either of the following antibodies:
Early disease as defined as onset of objective muscle weakness assessed by a physician and/or CK elevation attributed to IMNM within 1 year of the time of informed consent.
Muscle weakness as assessed by an MMT-8 score \< 142 of 150 and CK \> 1.5x ULN along with abnormality in at least 1 of the following 4 CSMs at screening:
PhGA ≥ 2 cm
PtGA ≥ 2 cm
Extramuscular global assessment ≥ 2 cm
HAQ-DI ≥ 0.25
Treatment with only one of the following background immunosuppressant medications for IMNM for at least 12 weeks prior to randomization and the same dose for at least 4 weeks prior to randomization:
Methotrexate up to 25 mg weekly
Mycophenolate mofetil up to 3000 mg daily
Mycophenolic acid up to 2160 mg daily
Azathioprine up to 2.5 mg/kg daily
Tacrolimus up to 0.2 mg/kg daily
Cyclosporine up to 5 mg/kg daily
Current therapy consisting of glucocorticoid ≤ 20 mg/day of prednisone. The dose must be stable for at least 4 weeks prior to randomization. Participants who stopped treatment with glucocorticoids are eligible if the last dose of the glucocorticoids was at least 4 weeks before the time of informed consent.
Female participants of childbearing potential and male participants with a partner of childbearing potential must agree to consistently and correctly use FDA approved highly effective methods of birth control, as shown in Appendix 1: Acceptable Contraception Methods for Females of Reproductive Potential, for the entire duration of the study and 6 months after last study drug infusion. Female participants of reproductive potential must have a negative pregnancy test at screening and at baseline.

Exclusion Criteria

End-stage myositis with end-organ involvement that poses additional risk to the participant or confounds the assessment of the participant in the study. Conditions include but are not limited to advanced symptomatic interstitial lung disease (e.g., Forced Vital Capacity (FVC) \<60% and/or requiring oxygen therapy) or severe dysphagia.
Irreversible muscle involvement and/or severe atrophy that will pose additional risk to the participant or confound the assessment of the participant in the study. This includes Muscle Damage VAS ≥ 3 cm at screening, documented history of severe atrophy of multiple muscle groups (based on MRI), and/or wheelchair bound.
Uncontrolled interstitial lung disease or any other uncontrolled IIM manifestation that in the opinion of the investigator would be likely to require treatment with prohibited medication during the study.
Diagnosis of other inflammatory or noninflammatory myopathies, including antibody-negative IMNM, inclusion body myositis, overlap myositis, metabolic myopathies, muscular dystrophies or family history of muscular dystrophy, drug induced, cancer-associated myositis, or endocrine-based myositis (except statin induced anti-HMGCR associated IMNM).
Severe liver disease, such as signs of ascites or hepatic encephalopathy.
History of malignancy (excluding non-melanoma skin cancer) unless cured by adequate treatment, with no evidence of recurrence for ≥ 5 years from the time of informed consent.
Recent or ongoing bacterial, viral, or fungal infection requiring systemic treatment within 14 days of the time of informed consent.
Current suppressive therapy for any chronic infections including herpes simplex virus (HSV).
Infection with Mycobacterium tuberculosis (TB) as defined by any of the following:
Positive interferon gamma release assay (IGRA) performed at screening or within 12 weeks prior to the time of informed consent.
Indeterminate IGRAs must be repeated (with same or other IGRA per local policy) and shown to be negative. Alternatively, if the assay remains indeterminant, a participant must have a negative purified protein derivative (PPD) skin test. Finally, if the participant has had the Bacille Calmette-Guerin (BCG) vaccine or has some other condition complicating the interpretation of TB testing, consultation with infectious disease specialist must be obtained before randomization.
Medical history or serologic evidence at screening of chronic infections, including: a. Human immunodeficiency virus (HIV) infection b. Hepatitis B virus (HBV) as indicated by surface antigen or hepatitis B core antibody positivity c. Hepatitis C virus (HCV) as indicated by anti-hepatitis C antibody positivity. If a participant is Hepatitis C antibody positive, they will be eligible to participate in the study if they have a negative viral load at Screening.
Known hypersensitivity reaction to ublituximab.
Received a live or live-attenuated vaccine \< 4 weeks before the time of informed consent. Received any other type of vaccine \< 2 weeks before the time of informed consent.
Any of the following laboratory tests at screening: a. Hemoglobin \< 10 g/dL b. Absolute white blood cell count \< 3,000 cells/mm3 c. Platelet count \< 100,000 cells/mm3 d. Absolute neutrophils \< 1,500 cell/mm3 e. Peripheral B-cell \< 40 cells/µL f. IgG \< 690 mg/dL g. Estimated GFR \< 50 mL/min/1.73 m2
Treatment with any immunosuppressive or immunomodulatory agent, such as cyclophosphamide, biologics, and Janus kinase (JAK) inhibitors, except those listed in the inclusion criteria 7 within 12 weeks prior to randomization.
Prior receipt of B-cell depleting agents such as rituximab, ocrelizumab, ofatumumab, or belimumab at any time.
Treatment of IMNM with IVIG or subcutaneous immunoglobulin (SCIG) within 12 weeks of randomization, or prior receipt of more than one cycle of IVIG at any time.
Participant has current or history (within 12 months of screening) of alcohol, drug, or medication abuse.
Participant is pregnant or lactating or intends to become pregnant during the study.
Use of any investigational drug within 24 weeks of the time of informed consent.
Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Great Neck?

Yes, this clinical trial (NCT07103746) has an active research site in Great Neck, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Necrotizing Myopathy Treatment Options in Great Neck, NY

If you're searching for necrotizing myopathy treatment options in Great Neck, NY, this clinical trial (NCT07103746) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Great Neck research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced necrotizing myopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Great Neck?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Great Neck, NY